China Biotech Services Holdings Limited (HKG:8037)
Hong Kong
· Delayed Price · Currency is HKD 0.670
+0.010 (1.52%)
Apr 29, 2026, 3:54 PM HKT
HKG:8037 Revenue
In the year 2025, China Biotech Services Holdings had annual revenue of 73.50M HKD with 4.25% growth. China Biotech Services Holdings had revenue of 34.63M in the half year ending December 31, 2025, with 16.89% growth.
Revenue
73.50M
Revenue Growth
+4.25%
P/S Ratio
8.89
Revenue / Employee
544.47K
Employees
135
Market Cap
653.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.50M | 2.99M | 4.25% |
| Dec 31, 2024 | 70.51M | -141.48M | -66.74% |
| Dec 31, 2023 | 211.99M | -1.64B | -88.55% |
| Dec 31, 2022 | 1.85B | 1.23B | 196.83% |
| Dec 31, 2021 | 623.76M | -32.03M | -4.88% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biosino Bio-Technology and Science Incorporation | 205.08M |
| Yunkang Group | 669.23M |
| Kindstar Globalgene Technology | 1.04B |
| Mega Genomics | 275.03M |
| Adicon Holdings | 2.94B |
| King International Investment | 77.50M |
| China Health Group | 31.79M |
| Guanze Medical Information Industry (Holding) | 98.42M |